Augmented-Medication CardioPulmonary Resuscitation (AMCPR) trial: a study protocol for a randomized controlled trial

Abstract

Background: Because most previous studies about the usefulness of vasopressin during resuscitation had been physician-oriented, it is necessary to evaluate with patient-centered. The aim of this study is to investigate whether Augmented-Medication CardioPulmonary Resuscitation (AMCPR) would enhance chance to return of spontaneous circulation (ROSC) in patients with out-of-hospital cardiac arrest.Methods: This is a double-blind, single-center, randomized placebo-controlled trial conducted in the emergency department in tertiary, university-affiliated hospital in Seoul, Korea. A total of 148 adult patients with non-traumatic, non-shockable, out-of-hospital cardiac arrest those who have initial diastolic blood pressure above 20 mmHg will be randomly assigned to two groups of 74 patients (1:1 ratio). Patients will receive intravenously a dose of 40 IU of vasopressin with epinephrine, or a placebo with epinephrine. The primary endpoint is a sustained ROSC (over 20 minutes). Secondary endpoints are enhancing diastolic blood pressures, end-tidal carbon dioxide levels, acidosis, and lactate levels during resuscitation.Discussion: AMCPR is a trial about tailor made medication for selected patients during resuscitation. This is a first randomized control trial to find patients who will be help to ROSC by vasopressin. This study will provide evidence about the effect of additional administration of vasopressin with epinephrine to increase the ROSC rate.

Augmented-Medication CardioPulmonary Resuscitation Trials in out-of-hospital cardiac arrest: a pilot randomized controlled trial

“…Additional file 1 : Fig. S1 presents the brief study protocol [ 12 ]. Emergency medicine physicians on duty tried to access the radial or femoral artery percutaneously using Arterial Leadercath (Vygon, France) within 6 min of admission of all eligible patients.…”